Evolus, Inc. (EOLS)
Current
- (-)
After Hours
Rating Performance
Rating Return
+32.46% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
+32.46% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
+32.46% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
+69.89% vs
Rating Accuracy
100.0% (2 of 2*)
FV Performance
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+101.91%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+155.15%
FV Accuracy
1 Hit (4.0% Hit Rate)
FV Avg. Distance
+144.57%
FV Accuracy
5 Hits (10.2% Hit Rate)
FV Avg. Distance
+110.39%
About
CEO
David Moatazedi
Employees
235
Industry
Dermatology Biopharmaceuticals
Sector
Healthcare
Headquarters
Newport Beach
Exchange
NASDAQ
Website
http://www.evolus.comSummary Stats
Market Cap
665M
Revenue
121M
Net Income
-70.7M
EPS
-$1.32
Price-to-Earnings
-8.99
Price-to-Book
9.89
Debt-to-Equity
2.28
News
Analyst Ratings
Price targets projected by 8 analysts
High
$35.00
Average
$10.62
Low
$4.00
Ratings calculated by 0 analysts
Buy
0
Hold
0
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Above by $0.02
-$0.31 +6.1%
-0.33
-0.44
Up 29%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--